MeVis Medical Solutions AG

Earnings Release • Aug 29, 2011

News Details

Corporate | 29 August 2011 07:00

MeVis records decline in sales in the first half of the year

MeVis Medical Solutions AG / Key word(s): Interim Report

29.08.2011 / 07:00

---

MeVis records decline in sales in the first half of the year

Strong growth in maintenance revenues unable to compensate for lower license sales

– Consolidated sales fall by 9% to EUR 6.7 m (previous year: EUR 7.3 m)

– Share of maintenance business rises to 43% (previous year: 30%)

– New license business drops 23% to EUR 3.6 m (previous year: EUR 4.7 m)

– Earnings before interest and taxes (EBIT) amount to EUR 0.2 m (previous year: EUR 0.2 m)

– High volume of deferred taxes impacts consolidated earnings of EUR -1.2 m (previous year: EUR -0.4 m)

Bremen, August 29, 2011 – Today, MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading software provider for the medical imaging market, announced its results for the first half of 2011. Consolidated sales for the first half of the year decreased by 9% to EUR 6.7 m due to the very weak second quarter. The composition of consolidated sales changed again in favor of the maintenance business. While this field carried on developing positively with sales growing by 18% to EUR 1,348 k (previous year: EUR 1,146 k), license sales dropped disproportionately by 26% to EUR 1,520 k (previous year: EUR 2,062 k). Increasing market saturation in our Digital Mammography key business in the important U.S. market and a further decline in the breast MRI business were the main factors contributing to this development.

The Digital Mammography business segment fell by only 3% to EUR 5,191 k (previous year: EUR 5,356 k) in the first half of 2011. This was due to the higher share of maintenance revenue, which accounted for 49% (previous year: 35%) of segment sales. Throughout the Group, the share of maintenance revenue went up to 43% (previous year: 30%) in the first half of the year.

New products in the Other Diagnostics segment continued to develop disappointingly. However, the 24% drop in segment sales to EUR 1,497 k (previous year: EUR 1,965 k) can mainly be attributed to further weakening of the breast MRI business in the U.S. sales market with our industry partner Invivo Corp. Business developments for the neurology (DynaSuite Neuro) and prostate (DynaCAD(R) Prostate) software applications, introduced in 2009 by Invivo Corp., were stable at a low level. Our lung product Visia(TM) CT-Lung System once again did not generate any significant sales in the past quarter. Maintenance revenue in this segment accounted for 25% of overall Other Diagnostics sales (previous year: 14%).

'Consolidation in the market is increasing at a very fast pace, and our new product revenues have not materialized as quickly as planned. Considering these factors and in view of our weakening license sales trend, we are accelerating our review and adjustment of various strategic business activities and plan to adapt them to the changing market environment. We will conclude this process by the end of the year, in close collaboration with our Supervisory Board,' said Dr. Carl J.G. Evertsz, CEO of MeVis Medical Solutions AG.

'Our ongoing strategic review involves optimizing our product development priorities, the company's platform software activities and our participation in the cardiovascular imaging market,' added Thomas E. Tynes, President & CEO of MeVis Medical Solutions, Inc., Pewaukee/USA, and member of the Executive Board of MeVis Medical Solutions AG.'

Staff costs again fell substantially by 11% to EUR 4,852 k (previous year: EUR 5,461 k) in the first half of the year, being a key reason why earnings before interest, taxes, depreciation and amortization (EBITDA) rose 2% to EUR 1,965 k (previous year: EUR 1,924 k). The number of personnel was 150 full-time equivalents at the end of the first half, down 17% on the previous year (181). Other operating expenses decreased slightly by 2% and came to EUR 1,431 k during the period under review (previous year: EUR 1,455 k). Our cost reduction measures therefore continued to prove effective.

Scheduled depreciation and amortization remained largely unchanged during the reporting period, standing at EUR 1,784 k (previous year: EUR 1,774). While depreciation and amortization on previously capitalized development costs increased, amortization on other acquired intangible assets fell on account of the balance sheet adjustment at the end of 2010. The rate of total capitalization, in other words the ratio between depreciation and amortization of capitalized development costs and newly recognized own development activities, amounted to 0.79 in the period under review (previous year: 0.75).

Earnings before interest and taxes (EBIT) of EUR 181 k did not change significantly compared to the previous year (EUR 150 k). The EBIT margin rose slightly to 2.7% (previous year: 2.1%).

At EUR -617 k, the financial result was down on the previous year (EUR -363 k). Pre-tax earnings therefore fell to EUR -435 k in the first half of the year (previous year: EUR -212 k). Taking into account much higher income tax expenses, largely defined by deferred tax expenditures with no impact on liquidity, the company is posting a loss of EUR -1,172 k for the first half of 2011 (previous year: EUR -652 k). Earnings per share therefore amount to EUR -0.68 (previous year: EUR -0.38). Deferred taxes are mainly the result of the strategic acquisition of shares in MeVis BreastCare Solutions held by Siemens and the capitalization of development expenses.

Liquid funds came to EUR 9,540 k at the end of the first half of the year (December 31, 2010: EUR 8,162 k).

'In view of business developments so far, we are confirming our forecast that was published in the Group management report 2010, in which we anticipated consolidated sales to drop slightly in the current financial year on account of the new license business decreasing throughout the Group in financial year 2010,' stated Dr. Robert Hannemann, member of the Executive Board of MeVis Medical Solutions AG. 'Consolidated earnings before interest and taxes (EBIT) should be slightly positive due to additional cost savings.'

Taking into consideration the development of U.S. dollar exchange rates, the currency in which around 80% of bills are invoiced within the Group, as well as current market and business developments, the Executive Board will define its forecast during the course of the financial year.

For further information please visit http://www.mevis.de .

End of Corporate News

---

29.08.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.

The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:	English
Company:	MeVis Medical Solutions AG
	Universitätsallee 29
	28359 Bremen
	Germany
Phone:	+49 421 224 95 0
Fax:	+49 421 224 95 11
E-mail:	ir@mevis.de
Internet:	http://www.mevis.de
ISIN:	DE000A0LBFE4
WKN:	A0LBFE
Listed:	Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News	DGAP News-Service

- - -
137173  29.08.2011